Association of Interleukin-6 -174G/C Polymorphism with the Risk of Diabetic Nephropathy in Type 2 Diabetes: A Meta-analysis

Abstract

Previous studies reported the association between interleukin-6 (IL-6) -174G/C gene polymorphism and the risk of diabetic nephropathy in type 2 diabetes mellitus (T2DN). However, the results remain controversial. In the present study, we conducted a meta-analysis to further examine this relationship between IL-6-174G/C gene polymorphism and T2DN. Three databases (PubMed, SinoMed and ISI Web of Science) were used to search clinical case-control studies about IL-6-174G/C polymorphism and T2DN published until Apr. 14, 2018. Fixed- or random-effects models were used to calculate the effect sizes of odds ratio (OR) and 95% confidence intervals (95% CI). Moreover, subgroup analysis was performed in terms of the excretion rate of albuminuria. All the statistical analyses were conducted using Stata 12.0. A total of 11 case-control studies were included in this study, involving 1203 cases of T2DN and 1571 cases of T2DM without DN. Meta-analysis showed that there was an association between IL-6-174G/C polymorphism and increased risk of T2DN under the allelic and recessive genetic models (G vs. C: OR=1.10, 95%CI 1.03–1.18, P=0.006; GG vs. CC+GC: OR=1.11, 95%CI 1.02–1.21 P=0.016). In the subgroup analysis by albuminuria, a significant association of IL-6-174G/C polymorphism with risk of T2DN was noted in the microalbuminuria group under the recessive model (OR=1.54, 95% CI 1.02–2.32, _P=0.038). In conclusion, this meta-analysis suggests that IL-6-174G/C gene polymorphism is associated with the risk of T2DN.

Keywords

interleukin-6 (IL-6)-174G/C gene polymorphism / diabetic nephropathy / type 2 diabetes mellitus / meta-analysis

References

[1] NyenweEA, JerkinsTW, UmpierrezGE, et al.. Management of type 2 diabetes: evolving strategies for the treatment of patients with type 2 diabetes. Metabolism, 2011, 60(1): 1-23

[2] AfkarianM, SachsMC, KestenbaumB, et al.. Kidney disease and increased mortality risk in type 2 diabetes. J Am Soc Nephrol, 2013, 24(2): 302-308

[3] CollinsAJ, FoleyRN, HerzogC, et al.. US Renal Data System 2010 Annual Data Report. Am J Kidney Dis, 2011, 57(1): A8,e1-A8,e526

[4] SuH, LeiCT, ZhangC. Interleukin-6 Signaling Pathway and Its Role in Kidney Disease: An Update. Front Immunol, 2017, 8: 405

[5] PfafflinA, BrodbeckK, HeiligCW, et al.. Increased glucose uptake and metabolism in mesangial cells overexpressing glucose transporter 1 increases interleukin-6 and vascular endothelial growth factor production: role of AP-1 and HIF-1alpha. Cell Physiol Biochem, 2006, 18(4–5): 199-210

[6] FishmanD, FauldsG, JefferyR, et al.. The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J Clin Invest, 1998, 102(7): 1369-1376

[7] SmithAJ, HumphriesSE. Cytokine and cytokine receptor gene polymorphisms and their functionality. Cytokine Growth Factor Rev, 2009, 20(1): 43-59

[8] AbrahamianH, EndlerG, ExnerM, et al.. Association of low-grade inflammation with nephropathy in type 2 diabetic patients: role of elevated CRP-levels and 2 different gene-polymorphisms of proinflammatory cytokines. Exp Clin Endocrinol Diabetes, 2007, 115(1): 38-41

[9] NgDP, NurbayaS, YeSH, et al.. An IL-6 haplotype on human chromosome 7p21 confers risk for impaired renal function in type 2 diabetic patients. Kidney Int, 2008, 74(4): 521-527

[10] PapaoikonomouS, TentolourisN, TousoulisD, et al.. The association of the 174G>C polymorphism of interleukin 6 gene with diabetic nephropathy in patients with type 2 diabetes mellitus. J Diabetes Complications, 2013, 27(6): 576-579

[11] KaradenizM, ErdoganM, BerdeliA, et al.. Association of interleukin-6 -174 G>C promoter polymorphism with increased risk of type 2 diabetes mellitus patients with diabetic nephropathy in Turkey. Genet Test Mol Biomarkers, 2014, 18(1): 62-65

[12] Zambrano-GalvanG, Reyes-RomeroMA, LazaldeB, et al.. Risk of microalbuminuria in relatives of subjects with diabetic nephropathy: a predictive model based on multivariable dimensionality reduction approach. Clin Nephrol, 2015, 83(2): 86-92

[13] RodriguesKF, PietraniNT, SandrimVC, et al.. Association of a Large Panel of Cytokine Gene Polymorphisms with Complications and Comorbidities in Type 2 Diabetes Patients. J Diabetes Res, 2015, 2015: 605965

[14] NeelofarK, AhmadJ, AhmadA, et al.. Study of IL4-590C/T and IL6-174G/C Gene Polymorphisms in Type 2 Diabetic Patients With Chronic Kidney Disease in North Indian Population. J Cell Biochem, 2017, 118(7): 1803-1809

[15] HameedI, MasoodiSR, MalikPA, et al.. Genetic variations in key inflammatory cytokines exacerbates the risk of diabetic nephropathy by influencing the gene expression. Gene, 2018, 661: 51-59

[16] SunT, MaF, WangW, et al.. Association between interleukin-6-174G>C and-634C>G polymorphism and diabetic nephropathy: a meta-analysis. Int J Clin Exp Med, 2017, 10(4): 5957-5966

[17] VallonV, ThomsonSC. Renal function in diabetic disease models: the tubular system in the pathophysiology of the diabetic kidney. Annu Rev Physiol, 2012, 74: 351-375

[18] WadaT, ShimizuM, ToyamaT, et al.. Clinical impact of albuminuria in diabetic nephropathy. Clin Exp Nephrol, 2012, 16(1): 96-101

[19] YangB, CrossDF, OllerenshawM, et al.. Polymorphisms of the vascular endothelial growth factor and susceptibility to diabetic microvascular complications in patients with type 1 diabetes mellitus. J Diabetes Complications, 2003, 17(1): 1-6

[20] BuraczynskaM, ZukowskiP, WacinskiP, et al.. Chemotactic cytokine receptor 5 gene polymorphism: relevance to microvascular complications in type 2 diabetes. Cytokine, 2012, 58(2): 213-217

[21] MooyaartAL, ValkEJ, van EsLA, et al.. Genetic associations in diabetic nephropathy: a meta-analysis. Diabetologia, 2011, 54(3): 544-553

[22] SkovL, BeurskensFJ, ZachariaeCO, et al.. IL-8 as antibody therapeutic target in inflammatory diseases: reduction of clinical activity in palmoplantar pustulosis. J Immunol, 2008, 181(1): 669-679

[23] VionnetN, TregouetD, KazeemG, et al.. Analysis of 14 candidate genes for diabetic nephropathy on chromosome 3q in European populations: strongest evidence for association with a variant in the promoter region of the adiponectin gene. Diabetes, 2006, 55(11): 3166-3174

[24] FathySA, MohamedMR, AliM, et al.. Influence of IL-6, IL-10, IFN-gamma and TNF-alpha genetic variants on susceptibility to diabetic kidney disease in type 2 diabetes mellitus patients. Biomarkers, 20181-13

[25] HojsR, EkartR, BevcS, et al.. Biomarkers of Renal Disease and Progression in Patients with Diabetes. J Clin Med, 2015, 4(5): 1010-1024

[26] IshiharaK, HiranoT. IL-6 in autoimmune disease and chronic inflammatory proliferative disease. Cytokine Growth Factor Rev, 2002, 13(4–5): 357-368

[27] NavarroJF, MilenaFJ, MoraC, et al.. Renal pro-inflammatory cytokine gene expression in diabetic nephropathy: effect of angiotensin-converting enzyme inhibition and pentoxifylline administration. Am J Nephrol, 2006, 26(6): 562-570

[28] SuzukiD, MiyazakiM, NakaR, et al.. In situ hybridization of interleukin 6 in diabetic nephropathy. Diabetes, 1995, 44(10): 1233-1238

[29] ChangWT, HuangMC, ChungHF, et al.. Interleukin-6 gene polymorphisms correlate with the progression of nephropathy in Chinese patients with type 2 diabetes: A prospective cohort study. Diabetes Res Clin Pract, 2016, 120: 15-23

[30] MysliwskaJ, ZorenaK, MysliwiecM, et al.. The -174GG interleukin-6 genotype is protective from retinopathy and nephropathy in juvenile onset type 1 diabetes mellitus. Pediatr Res, 2009, 66(3): 341-345

[31] UrurahyMA, de SouzaKS, OliveiraYM, et al.. Association of polymorphisms in IL6 gene promoter region with type 1 diabetes and increased albumin-to-creatinine ratio. Diabetes Metab Res Rev, 2015, 31(5): 500-506